**Disease Area Educational Course on**

**Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), and Myelodysplastic Syndromes (MDS)**

**November 6–7, 2020 (CDT)/November 7–8, 2020 (CST)**

**Agenda Day 1: AML**

**Nov. 6**: 5.00 pm -12.00 am Houston time (CDT)

**Nov. 7:** 7.00 am – 2.00 pm Taiwan time (CST)

*Instructions: All attendees use link 1 and dial into room 1*

|  |  |
| --- | --- |
| **5.00 pm CDT/** **7.00 am CST**  | **Welcome, Introduction, and Description of Program**Co-chairs:*Naval Daver, MD, and Elias Jabbour, MD**Taiwan moderator: Hwei-Fang Tien, MD and Hsin-An Hou, MD* |
| **5.10 pm CDT/** **7.10 am CST** | **How I Treat AML: An Overview** *(30-min presentation; 10-min Q&A)**Hagop Kantarjian, MD* |
| **5.50 pm CDT/** **7.50 am CST** | **Management of Elderly Unfit and Fit AML** *(30-min presentation; 10-min Q&A)**Elias Jabbour, MD* |
| **6.30 pm CDT/** **8.30 am CST** | **Novel Therapies in AML** *(20-min presentation; 10-min Q&A)**Naval Daver, MD* |
| **7.00 pm CDT/** **9.00 am CST** | ***Break*** |
| **7.15 pm CDT/** **9.15 am CST** | **Post-HSCT maintenance***(30-min presentation; 10-min Q&A)**Issa Khouri, MD* |
| **7.55 pm CDT/** **9.55 am CST** | **BCL2-Based Therapies in AML** *(30-min presentation; 10-min Q&A)**Courtney DiNardo, MD, MSCE* |
| **8.35 pm CDT/** **10.35 am CST** | **MRD in AML and Role of Maintenance Therapy AML***(30-min presentation; 10-min Q&A)**Farhad Ravandi, MD* |
| **9.15 pm CDT/** **11.15 am CST** | **Panel Discussion (Moderated by Marina Konopleva, MD)***Naval Daver, MD; Elias Jabbour, MD; Issa Khouri, MD; Courtney DiNardo, MD, MSCE; Farhad Ravandi, MD; Tapan Kadia, MD; local facilitators* |
| **9.30 pm CDT/** **11.30 am CST** | **Welcome Note from AbbVie and Affiliate Delegate Introduction Followed by Lunch Break** |

*Instructions: Group 1 remains in current link 1 and dials into room 1; Group 2 logs into link 2 and dials into room 2; Group 3 logs into link 3 and dials into room 3*

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **10.30 pm CDT/** **12.30 pm CST** | **Patient Case Workshops** (3 small groups; 3 rotations)1. **Newly Diagnosed Adult AML Young, Fit**

*Elias Jabbour, MD + Shilpa Paul, PharmD, BCOP + Jyh-Pyng Gau, MD (Taiwan)*1. **Newly Diagnosed Elderly AML >75 years**

*Tapan Kadia, MD + Mary Alma Welch, PA-C + Hsin-An Hou, MD (Taiwan)*1. **Newly Diagnosed Secondary AML 60–75 years: Borderline Fitness**

*Naval Daver, MD + Megan Wiese, MS, PA-C* *+ Bor-Sheng Ko, MD (Taiwan)*

|  |  |  |  |
| --- | --- | --- | --- |
| **Time CDT/*CST*** | **Group 1** | **Group 2** | **Group 3** |
| 10.30 pm – 11.00 pm*12.30 pm – 1.00 pm*  | A | B | C |
| 11.00 pm – 11.30 pm*1.00 pm – 1.30 pm*  | C | A | B |
| 11.30 pm – 12.00 am*1.30 pm – 2.00 pm*  | B | C | A |

 |
| **12.00 am CDT/** **2.00 pm CST** | **End of Day 1** |

**Agenda Day 2: CLL and MDS**

**Nov. 7**: 4.00 pm – 12.00 am Houston time (CDT)

**Nov. 8:** 6.00 am – 2.00 pm Taiwan time (CST)

*Instructions: All attendees use link 1 and dial in to room 1*

|  |  |
| --- | --- |
| **4.00 pm CDT/** **6.00 am CST** | **Welcome Back, Interval Announcements***Naval Daver, MD, and Elias Jabbour, MD* *Taiwan Moderators: Wen-Chien Chou, MD and Cheng-Shyong Chang, MD* |
| **4.15 pm CDT/** **6.15 am CST**  | **CLL: An Overview***(20-min presentation; 5-min Q&A)**William Wierda, MD, PhD* |
| **4.40 pm CDT/** **6.40 am CST** | **Updates in First-Line CLL***(30-min presentation; 10-min Q&A)**Nitin Jain, MD* |
| **5.20 pm CDT/** **7.20 am CST** | **Coffee Break** |
| **5.30 pm CDT/** **7.30 am CST** | **Management of Relapsed/Refractory CLL***(30-min presentation; 10-min Q&A)**William Wierda, MD, PhD* |
| **6.10 pm CDT/** **8.10 am CST** | **BCL2 Inhibition in CLL: Single-Agent and Combo Approaches***(30-min presentation; 10-min Q&A)**Alessandra Ferrajoli, MD* |
| **6.50 pm CDT/** **8.50 am CST** | ***Break*** |
| **7.50 pm CDT/** **9.50 am CST** | **MRD in CLL** *(20-min presentation; 10-min Q&A)**Philip Thompson, MD* |
| **8.20 pm CDT/** **10.20** **am CST**  | **Biology and Pathology of MDS***(20-min presentation; 10-min Q&A)**Rashmi Kanagal, MD* |
| **8.50 pm CDT/** **10.50 am CST** | **Low- and High-Risk MDS: Management Approaches***(30-min presentation; 10-min Q&A)**Guillermo Garcia-Manero, MD*  |
| **9.30 pm CDT/** **11.30 am CST** | **Emerging Therapies in MDS***(30-min presentation; 10-min Q&A)**Guillermo Montalban-Bravo, MD* |
| **10.10 pm CDT/** **12.10 am CST** | **Transition to Patient Case Workshops** |

*Instructions: Group 1 remains in current link 1 and dials into room 1; Group 2 logs into link 2 and dials into room 2; Group 3 logs into link 3 and dials into room 3*

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **10.15 pm CDT/** **12.15 pm CST** | **Patient Case Workshops** (3 small groups; 3 rotations)1. **Newly Diagnosed CLL**

*Nitin Jain, MD + Caitlin Rausch, PharmD + Su-Peng Yeh, MD (Taiwan)*1. **Relapsed/Refractory CLL**

*Philip Thompson, MD + Jill Vershel, MS, PA-C + Tran-Der Tan, MD (Taiwan)*1. **MDS**

*Guillermo Garcia-Manero, MD + Kelsey Moakler, PA + Hsin-An Hou, MD (Taiwan)*

|  |  |  |  |
| --- | --- | --- | --- |
| **Time CDT/*CST*** | **Group 1** | **Group 2** | **Group 3** |
| 10.15 pm – 10.45 pm *12.15 pm – 12.45 pm*  | A | B | C |
| 10.45 pm – 11.15 pm *12.45 pm – 1.15 pm*  | C | A | B |
| 11.15 pm – 11.45 pm *1.15 pm – 1.45 pm*  | B | C | A |

 |
| **11.45 pm CDT/** **1.45 pm CST** | **Transition to Panel Q&A** |
| **11.50 pm CDT/** **1.50** **pm CST** | **Panel Q&A and Closing Remarks (moderated by Guillermo Garcia-Manero, MD)***Naval Daver, MD; Elias Jabbour, MD; Nitin Jain, MD; Philip Thompson, MD; William Wierda, MD, PhD; Alessandra Ferrajoli, MD; Rashmi Kanagal, MD; Guillermo Garcia-Manero, MD; Guillermo Montalban-Bravo, MD; local facilitators* |
| **12.00 am CDT/** **2.00 pm CST** | **Program Evaluation and Log Out** |